Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus
JF Trotter, ME Wachs, TE Trouillot, T Bak… - Liver Transplantation, 2001 - Elsevier
Since its approval as an immunosuppressive agent in renal transplantation, sirolimus
(RAPA) recently has been used in the primary immunosuppression regimen at several liver
transplant centers. One of the major side effects of RAPA is hypercholesterolemia, which is
reported in up to 44% of patients. We describe our experience in 57 primary liver transplant
recipients treated with RAPA and either cyclosporine A (CSA) or tacrolimus (TAC). We report
the incidence and severity of hypercholesterolemia using a prednisone-free …
(RAPA) recently has been used in the primary immunosuppression regimen at several liver
transplant centers. One of the major side effects of RAPA is hypercholesterolemia, which is
reported in up to 44% of patients. We describe our experience in 57 primary liver transplant
recipients treated with RAPA and either cyclosporine A (CSA) or tacrolimus (TAC). We report
the incidence and severity of hypercholesterolemia using a prednisone-free …
